Merck & Co. Inc. reported total worldwide sales of $17.3 billion for the third quarter of 2025, reflecting a 4% increase compared to $16.7 billion in the same period of 2024. Excluding the impact of foreign exchange, sales grew by 3%. Pharmaceutical sales reached $15.6 billion, up 4%, primarily driven by growth in oncology, cardiovascular, and diabetes products, which offset declines in vaccines, virology, and immunology. Keytruda sales rose 10% to $8.1 billion, or 8% excluding foreign exchange effects. Winrevair sales were $360 million, an increase of 141%. Capvaxive sales totaled $244 million. Gardasil and Gardasil 9 sales declined 24% to $1.7 billion, or 25% excluding foreign exchange. Animal Health sales grew 9% to $1.6 billion, or 7% excluding foreign exchange. GAAP net income for the quarter was $5.8 billion, up 83% from $3.2 billion in the prior-year period. Non-GAAP net income was $6.4 billion, a 62% increase. GAAP earnings per share $(EPS)$ were $2.32, up 87%, while non-GAAP EPS was $2.58, up 64%. Both GAAP and non-GAAP EPS included a $0.10 per share charge related to a milestone payment for technology transfer. Merck raised and narrowed its expected worldwide sales guidance for the full year 2025 to between $64.5 billion and $65.0 billion. The company also updated its expected non-GAAP EPS range to $8.93 to $8.98. During the quarter, Merck completed the acquisition of Verona Pharma and expanded its U.S. manufacturing and R&D investments.